Industry News
The FDA Is Getting a New Boss: What Heidi Overton's Nomination Means for Tobacco
The agency that decides which nicotine products can be sold in America is about to change hands again. On August 19, President Trump announced via Truth Social that he will nominate Dr. Heidi Overton, a White House health-policy aide, as FDA Commissioner — filling a seat vacant since Marty Makary's contentious May resignation.
For the tobacco and nicotine world, the pick lands in the middle of the most industry-friendly stretch of FDA policy in a decade, and the open question is whether Overton keeps it rolling.
Who is Dr. Heidi Overton?
Overton is a physician — University of New Mexico M.D., surgical training and a clinical-investigation doctorate at Johns Hopkins — who came up through policy rather than agency ranks. She served as a White House fellow in Trump's first term, chief policy officer at the America First Policy Institute, and currently deputy director of the Domestic Policy Council.
Trump called her a "rockstar" and tied the pick to the administration's MAHA health agenda. Notably for this audience, she has almost no public record on tobacco or nicotine issues — a blank slate atop an agency making consequential nicotine decisions monthly.
Her predecessor's exit is part of the story. Makary resigned in May amid White House tensions that reportedly included flavored e-cigarettes — he resisted authorizing them while others in the administration pushed for approval. Kyle Diamantas has been acting commissioner since. Confirmation is not a formality: Senate HELP chair Bill Cassidy has flagged Overton's thin management experience, and Democrats led by Patty Murray have announced opposition.
The Tobacco Center She Would Inherit
The FDA's Center for Tobacco Products has been run since 2025 by acting director Bret Koplow, and his tenure has quietly transformed the agency's posture. The premarket-application backlog fell roughly 70% in 2025; applications now enter substantive review almost immediately; and a fast-track "supplemental" pathway serves modified products.
Koplow has publicly embraced the "continuum of risk" view that pouches, vapes, and heated tobacco sit below cigarettes.
A nicotine-pouch pilot authorized six products in about three months — the template behind August's rapid ZYN Ultra authorizations. Enforcement guidance issued in May formally deprioritizes action against vapes and nicotine pouches with pending applications, focusing instead on products with no application, youth-appealing designs, or illicit-import origins.
A permanent commissioner decides whether that direction — and Koplow himself — stays. The pending decisions are substantial: flavored-vape applications the last commissioner reportedly resigned over, the graphic-warnings litigation, and a growing docket of pouch and heated tobacco applications.
What It Means for Shoppers and Retailers
Nothing changes at the counter tomorrow — and that's the point of watching. The FDA's recent pattern of faster authorizations and lighter enforcement has directly shaped what's on shelves this year, from ZYN Ultra to newly authorized on! pouches.
A confirmed commissioner aligned with that approach would entrench it; a stalled or contentious confirmation leaves the agency running on acting officials, which historically means fewer big decisions. Public-health groups, meanwhile, are already suing the FDA for under-enforcement — so the new boss inherits litigation from both directions.
The Bottom Line
Overton arrives with no tobacco track record at an agency whose tobacco products policy is mid-pivot. Watch the confirmation hearing: the first time a senator asks her about flavored vapes or nicotine pouches will tell the industry more than the nomination announcement did.